Targeting phagocytosis to enhance antitumor immunity.

adaptive immunity dendritic cells innate immunity macrophages phagocytic checkpoints

Journal

Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956

Informations de publication

Date de publication:
08 2023
Historique:
received: 10 03 2023
revised: 10 04 2023
accepted: 14 04 2023
medline: 21 7 2023
pubmed: 8 5 2023
entrez: 7 5 2023
Statut: ppublish

Résumé

Many patients with metastatic or treatment-resistant cancer have experienced improved outcomes after immunotherapy that targets adaptive immune checkpoints. However, innate immune checkpoints, which can hinder the detection and clearance of malignant cells, are also crucial in tumor-mediated immune escape and may also serve as targets in cancer immunotherapy. In this review, we discuss the current understanding of immune evasion by cancer cells via disruption of phagocytic clearance, and the potential effects of blocking phagocytosis checkpoints on the activation of antitumor immune responses. We propose that a more effective combination immunotherapy strategy could be to exploit tumor-intrinsic processes that inhibit key innate immune surveillance processes, such as phagocytosis, and incorporate both innate and adaptive immune responses for treating patients with cancer.

Identifiants

pubmed: 37150626
pii: S2405-8033(23)00062-6
doi: 10.1016/j.trecan.2023.04.006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

650-665

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests No interests are declared by the author.

Auteurs

Kristin Huntoon (K)

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

DaeYong Lee (D)

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Shiyan Dong (S)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abin Antony (A)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Betty Y S Kim (BYS)

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: BYKim@mdanderson.org.

Wen Jiang (W)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: WJiang4@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH